GNRH1 and osteoporosis: Use of LHRH + exemestane was associated with an increased incidence of osteoporosis by DXA criteria (38.6% vs. 25.2%) and increased fracture rates (6.8% vs. 5.2%) when compared to LHRH + tamoxifen over 5 years [120].